Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › prurigo nodularis

Prurigo nodularis

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for prurigo nodularis

16 trials tracked for prurigo nodularis: 10 in phase 3 or 4 and 4 with published results. The most-cited published study has 169 citations.

16Trials tracked
10Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 9 Phase 2 6
  1. Phase 3 Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Completed · 169 cited
  2. Phase 3 A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Completed · 163 cited
  3. Phase 3 Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis Completed · 49 cited
  4. Phase 4 Pain Outcomes Following Intralesional Corticosteroid Injections Completed · 9 cited
  5. Phase 3 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis Completed
  6. Phase 3 Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis Completed
Show 10 more trials
  1. Phase 3 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis Completed
  2. Phase 3 A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis Completed
  3. Phase 3 PRISM Study-Pruritus Relief Through Itch Scratch Modulation Completed
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Completed
  5. Phase 2 Safety and Efficacy of CC-10004 for Prurigo Nodularis Completed
  6. Phase 2 A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) Completed
  7. Phase 2 A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis Completed
  8. Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis Completed
  9. Phase 2 Safety and Efficacy of Nemolizumab in PN Completed
  10. Phase 2 Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin Completed

Showing the 16 most-cited and recently-updated of 16 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Prurigo nodularis: what the trials found

Nemolizumab has demonstrated significant efficacy in improving pruritus and clinical outcomes. In two Phase 3 trials, patients receiving Nemolizumab showed significantly higher rates of achieving a ≥ 4-point improvement on the Peak Pruritus Numeric Rating Scale (PP NRS) at both Week 4 and Week 16 compared to placebo [3, 4]. Additionally, Nemolizumab was associated with significantly higher Investigator Global Assessment (IGA) success rates at Week 16 [3, 4]. Long-term data showed high rates of maintaining IGA success through scheduled visits 8.

Nalbuphine ER tablets demonstrated statistically significant improvements in itch intensity and quality of life. Patients treated with Nalbuphine showed a significantly higher percentage of ≥ 4-point decreases in the Worst Itch Numeric Rating Scale (WI-NRS) at Week 14 7. This was accompanied by significant improvements in the Itch-related Quality of Life (ItchyQoL) score and the Prurigo Activity Score (PAS) 7.

Serlopitant trials showed mixed results regarding responder rates. In one study, there was no statistically significant difference between Serlopitane and placebo for WI-NRS 4-point responder rates at Week 10 9. However, in another trial, a significantly higher percentage of patients achieved a WI-NRS 4-point response at Week 4 when treated with 5mg Serlopitant compared to placebo 11.

Other interventions include the use of corticosteroid with lidocaine 2, nalbuphine HCl ER tablets [5, 10], and Ruxolitinib Cream. However, Ruxolitinib Cream did not show statistically significant improvements in WI-NRS4 response at Week 4 or Week 12, nor did it show a significant difference in overall treatment success at Week 12 6.

Recent results — preliminary, needs further review

  • Vixarelimab showed a statistically significant reduction in the Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) score across multiple cohorts 1.
  • Vixarelimab also demonstrated a significant percentage reduction in Pruritus Visual Analog Scale (VAS) at Week 8 1.

For the clinician treating this condition

  • Nemolizumab is associated with statistically significant improvements in peak pruritus scores and investigator-assessed success rates [3, 4].
  • Nalbuphine ER tablets are effective for reducing worst itch intensity and improving patient quality of life 7.
  • Evidence for Serlopitan is mixed; while one trial showed no difference at Week 10, another showed significant improvement at Week 4 [9, 11].

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.